Hodgkin Lymphoma. A Comprehensive Overview PDF
Preview Hodgkin Lymphoma. A Comprehensive Overview
Hematologic Malignancies Series Editor: Martin Dreyling Andreas Engert Anas Younes Editors Hodgkin Lymphoma A Comprehensive Overview Third Edition Hematologic Malignancies Series Editor Martin Dreyling München, Germany Andreas Engert • Anas Younes Editors Hodgkin Lymphoma A Comprehensive Overview Third Edition Editors Andreas Engert Anas Younes Department of Internal Medicine Lymphoma Service University Hospital Cologne Memorial Sloan Kettering Cancer Köln, Nordrhein-Westfalen Center Germany NY, USA ISSN 2197-9766 ISSN 2197-9774 (electronic) Hematologic Malignancies ISBN 978-3-030-32481-0 ISBN 978-3-030-32482-7 (eBook) https://doi.org/10.1007/978-3-030-32482-7 © Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland Preface Hodgkin lymphoma has become one of the best curable malignancies in both adult and pediatric patients. More than 80% of all patients can be cured with risk-adapted treatment including chemotherapy and radiotherapy. This prog- ress is largely due to the development of multi-agent chemotherapy and the improvements in radiotherapy. Due to the high cure rate and the young age of most patients affected, Hodgkin lymphoma has also become a model for studying long-term toxicity of radiotherapy and chemotherapy that may impact quality of life and/or sur- vival. Future treatment should continue to balance the need for improving the cure rate while reducing treatment-related side effects. In addition, there are a number of relevant physical and psychosocial issues including infertility and fatigue that need to be further exploited. Monoclonal antibodies against this antigen were successfully used for diagnostic immunophenotyping and exploited therapeutically. This strategy has come full circle with the advent of the anti-CD30 antibody drug conju- gate Brentuximab Vedotin. This drug has shown remarkable responses in relapsed and refractory classical Hodgkin lymphoma and is also being used in combination with chemotherapy. The development of targeted treatment for patients with Hodgkin lym- phoma is rapidly evolving. The recent approval of checkpoint inhibitors has added an additional treatment option for patients with relapsed cHL, opening the door for new developments including new combinations of chemotherapy or radiotherapy being evaluated in first line. This book should give you a comprehensive overview of the most relevant biology, diagnostic and clinical aspects of Hodgkin lymphoma. We would like to express our sincere gratitude to all those who have contributed to this project. Cologne, Germany Andreas Engert New York, NY, USA Anas Younes v Contents Part I E pidemiology and Pathogenesis 1 Epidemiology of Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . 3 Henrik Hjalgrim and Ruth F. Jarrett 2 The Role of Viruses in the Genesis of Hodgkin Lymphoma . . . . . 25 Ruth F. Jarrett, Henrik Hjalgrim, and Paul G. Murray 3 Pathology and Molecular Pathology of Hodgkin Lymphoma . . . . 47 Andreas Rosenwald and Ralf Küppers 4 Microenvironment, Cross-Talk, and Immune Escape Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Lydia Visser, Johanna Veldman, Sibrand Poppema, Anke van den Berg, and Arjan Diepstra 5 What Have We Learnt from Genomics and Transcriptomics in Classic Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . 87 Davide Rossi and Christian Steidl Part II D iagnosis and First-Line Treatment 6 Clinical Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 James O. Armitage and Jonathan W. Friedberg 7 Functional Imaging in Hodgkin Lymphoma . . . . . . . . . . . . . . . . 113 Andrea Gallamini, Bruce Cheson, and Martin Hutchings 8 Prognostic Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145 Paul J. Bröckelmann and Lena Specht 9 Principles of Radiation Therapy for Hodgkin Lymphoma . . . . . 171 Joachim Yahalom, Bradford S. Hoppe, Joanna C. Yang, and Richard T. Hoppe 10 Principles of Chemotherapy in Hodgkin Lymphoma . . . . . . . . . 199 David Straus and Mark Hertzberg 11 Treatment of Early Favorable Hodgkin Lymphoma . . . . . . . . . . 219 Wouter Plattel and Pieternella Lugtenburg vii viii Contents 12 Treatment of Early Unfavorable Hodgkin Lymphoma . . . . . . . . 237 Marc P. E. André and Andreas Engert 13 Treatment of Advanced-Stage Hodgkin Lymphoma . . . . . . . . . . 249 Alexander Fosså, René-Olivier Casasnovas, and Peter W. M. Johnson 14 Optimizing Decision Making in Hodgkin Lymphoma . . . . . . . . . 265 Susan K. Parsons, Joshua T. Cohen, and Andrew M. Evens Part III Special Clinical Situations 15 Pediatric Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277 Georgina W. Hall, Cindy Schwartz, Stephen Daw, and Louis S. Constine 16 The Management of Older Patients with Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297 Boris Böll and Andrew M. Evens 17 Nodular Lymphocyte-Predominant Hodgkin Lymphoma . . . . . 317 Dennis A. Eichenauer and Ranjana H. Advani 18 The Management of Hodgkin Lymphoma During Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325 Veronika Bachanova and Joseph M. Connors 19 The Management of HIV-Hodgkin Lymphoma . . . . . . . . . . . . . . 335 Marcus Hentrich and Michele Spina Part IV R elapsed and Refractory Disease 20 Relapsed and Refractory Hodgkin Lymphoma . . . . . . . . . . . . . . 351 Bastian von Tresckow and Craig Moskowitz 21 Allogeneic Transplantation for Relapsed Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365 Anna Sureda, Martina Pennisi, and Paolo Corradini 22 Targeting CD30 in Patients with Hodgkin Lymphoma . . . . . . . . 381 Anita Kumar, Stefano Pileri, Anas Younes, and Andreas Engert 23 Hodgkin Lymphoma and PD-1 Blockade . . . . . . . . . . . . . . . . . . . 395 Reid Merryman, Philippe Armand, and Stephen Ansell 24 Other New Agents for Hodgkin Lymphoma . . . . . . . . . . . . . . . . . 411 Alison J. Moskowitz and Anas Younes Part V S urvivorship 25 Quality of Life in Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . 419 Stefanie Kreissl, Hans-Henning Flechtner, and Peter Borchmann Contents ix 26 Second Malignancy Risk After Treatment of Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 Michael Schaapveld, David C. Hodgson, and Flora E. van Leeuwen 27 Cardiovascular and Pulmonary Late Effects . . . . . . . . . . . . . . . . 465 Berthe M. P. Aleman and David J. Cutter 28 Gonadal Dysfunction and Fertility Preservation in Hodgkin Lymphoma Patients . . . . . . . . . . . . . . . . . . . . . . . . . . 485 Karolin Behringer and Michael von Wolff 29 Cancer-Related Fatigue in Hodgkin Lymphoma . . . . . . . . . . . . . 501 Stefanie Kreissl, Anton Hagenbeek, Hans Knoop, and Peter Borchmann Part I Epidemiology and Pathogenesis 1 Epidemiology of Hodgkin Lymphoma Henrik Hjalgrim and Ruth F. Jarrett Contents 1.1 Introduction 4 1.2 Definition and Histological Classification (WHO) 4 1.3 Hodgkin Lymphoma Occurrence 5 1.3.1 Overall Incidence 5 1.3.2 Ag e-Specific Incidence Patterns Vary Geographically 5 1.3.2.1 Historical Patterns 5 1.3.2.2 Modern Age-Specific Incidence Patterns 6 1.3.2.3 Age-Specific Incidence Patterns for Hodgkin Lymphoma Subtypes 7 1.3.3 Incidence Trends 7 1.3.4 Classifications for Epidemiological Studies: Multi-disease Models 10 1.3.5 Classifications by Age at Diagnosis, Histology and Tumour Epstein-Barr Virus Status 10 1.3.6 Overlap Between Epidemiological Classifications of Hodgkin Lymphoma 11 1.4 Familial Accumulation of Hodgkin Lymphoma: Genetic Predisposition 12 1.4.1 Genetic Studies: Genome-W ide Association Studies 12 1.4.1.1 Hodgkin Lymphoma Subtype- Specific Associations in Genetic Analyses 12 1.5 Risk Factors 13 1.5.1 Prevailing Hypotheses in Hodgkin Lymphoma Epidemiology 13 1.5.1.1 Childhood Socio-Economic Environment 13 1.5.2 Anthropometry 14 H. Hjalgrim (*) Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark Department of Haematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark e-mail: [email protected] R. F. Jarrett MRC-University of Glasgow Centre for Virus Research, Glasgow, UK © Springer Nature Switzerland AG 2020 3 A. Engert, A. Younes (eds.), Hodgkin Lymphoma, Hematologic Malignancies, https://doi.org/10.1007/978-3-030-32482-7_1
The list of books you might like
